<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="657f48b0-40b3-4a06-a244-741044b43d7d"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use </content>
      <content styleCode="bold">KYBELLA</content>
      <content styleCode="bold"> safely and effectively.  See full prescribing information for </content>
      <content styleCode="bold">KYBELLA</content>
      <content styleCode="bold">.</content>
      <br/>
      <content styleCode="bold"> </content>
      <content styleCode="bold">     </content>
      <br/>
      <content styleCode="bold">KYBELLA</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold"> (</content>
      <content styleCode="bold">d</content>
      <content styleCode="bold">eoxycholic acid</content>
      <content styleCode="bold">)</content>
      <content styleCode="bold"> </content>
      <content styleCode="bold">injection</content>
      <content styleCode="bold">,</content>
      <content styleCode="bold"> </content>
      <content styleCode="bold">for </content>
      <content styleCode="bold">subcutaneous</content>
      <content styleCode="bold"> use</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: </content>
      <content styleCode="bold">2015</content>
      <br/>
   </title>
   <effectiveTime value="20241030"/>
   <setId root="fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553"/>
   <versionNumber value="24"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="800791118" root="1.3.6.1.4.1.519.1"/>
            <name>Kythera Biopharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="9c946a42-bc2c-4f06-b879-75745bb36aac"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250314"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="61168-101" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>KYBELLA</name>
                        <formCode code="C42945" displayName="INJECTION, SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Deoxycholic Acid</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="mL" value="2"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="005990WHZZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEOXYCHOLIC ACID</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="005990WHZZ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEOXYCHOLIC ACID</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="18"/>
                              <denominator unit="mL" value="2"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="LKG8494WBH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="2.84"/>
                              <denominator unit="mL" value="2"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="GR686LBA74" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="8.76"/>
                              <denominator unit="mL" value="2"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="2.86"/>
                              <denominator unit="mL" value="2"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="2"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61168-101-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43209" displayName="VIAL, GLASS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="61168-101-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20150608"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="2"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="61168-101-91" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43209" displayName="VIAL, GLASS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="61168-101-94" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20150608"/>
                                          <high value="20220130"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="2"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43209" displayName="VIAL, GLASS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="2"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="61168-101-03" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180801"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA206333" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150608"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" displayName="SUBCUTANEOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="_1_INDICATIONS_AND">
               <id root="a44c68a3-1f57-44bc-bb19-4864a866381d"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1</content>
                  <content styleCode="bold">
		     
	INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>KYBELLA<sup>®</sup> (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Limitations of use</content>
                  </paragraph>
                  <paragraph>The safe and effective use of KYBELLA for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>KYBELLA<sup> </sup>is a cytolytic drug indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. (<linkHtml href="#_1_INDICATIONS_AND">1</linkHtml>)</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limit</content>
                           <content styleCode="underline">ation</content>
                           <content styleCode="underline">s</content>
                           <content styleCode="underline"> of use</content>
                        </paragraph>
                        <paragraph>The safe and effective use of KYBELLA for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended. (<linkHtml href="#_1_INDICATIONS_AND">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="1d30fce0-7dd1-4dab-bdb1-5f163a3baa28"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2</content>
                  <content styleCode="bold">
		     
	DOSAGE AND ADMINISTRATION</content>
               </title>
               <effectiveTime value="20241030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>0.2 mL injections spaced 1 cm apart until all sites in the planned treatment area have been injected. (<linkHtml href="#_2_1__Dosage">2.1</linkHtml>)<br/>
                           </item>
                           <item>Up to 50 injections or 10 mL may be injected in a single treatment. (<linkHtml href="#_2_1__Dosage">2.1</linkHtml>)<br/>
                           </item>
                           <item>Up to 6 single treatments may be administered at intervals no less than 1-month apart. (<linkHtml href="#_2_1__Dosage">2.1</linkHtml>)<br/>
                           </item>
                           <item>See General Considerations for Administration and Injection Technique before injection. (<linkHtml href="#_2_2__General">2.2</linkHtml>, <linkHtml href="#_2_3__Injection">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <observationMedia ID="MM03000001">
                     <text>Figure 1.  Avoid the Marginal Mandibular Nerve Area</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="kybella-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000002">
                     <text>Figure 2. Sagittal View of Platysma Area</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="kybella-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000003">
                     <text>Figure 3. Injection Pattern</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="kybella-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section ID="_2_1__Dosage">
                     <id root="a7fb6510-19ff-4a0a-8d08-a8dbb25f21c0"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 </content>
		     
	<content styleCode="bold">Dos</content>
                        <content styleCode="bold">age</content>
                     </title>
                     <text>
                        <paragraph>KYBELLA<sup> </sup>injection is injected into subcutaneous fat tissue in the submental area using an area-adjusted dose of 2 mg/cm<sup>2</sup>. </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>A single treatment consists of up to a maximum of 50 injections, 0.2 mL each (up to a total of 10 mL), spaced 1 cm apart.<br/>
                           </item>
                           <item>Up to 6 single treatments may be administered at intervals no less than 1 month apart.</item>
                        </list>
                        <paragraph>See <content styleCode="italics">General Considerations for Administration </content>
                           <content styleCode="italics">(</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_2__General">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">)</content> and <content styleCode="italics">Injection Technique </content>
                           <content styleCode="italics">(</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_3__Injection">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">)</content> before injection.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_2__General">
                     <id root="6da6bd89-30c4-4a55-9f26-8240038caf01"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 </content>
		     
	<content styleCode="bold">General Considerations for Administration</content>
                     </title>
                     <text>
                        <paragraph>KYBELLA should be administered by a healthcare professional.  </paragraph>
                        <paragraph>Screen patients for other potential causes of submental convexity/fullness (e.g., thyromegaly and cervical lymphadenopathy).</paragraph>
                        <paragraph>Give careful consideration to the use of KYBELLA in patients with excessive skin laxity, prominent platysmal bands or other conditions for which reduction of submental fat may result in an aesthetically undesirable outcome.</paragraph>
                        <paragraph>Use caution in patients who have had prior surgical or aesthetic treatment of the submental area. Changes in anatomy/landmarks or the presence of scar tissue may impact the ability to safely administer KYBELLA or to obtain the desired aesthetic result.  </paragraph>
                        <paragraph>KYBELLA is clear, colorless and free of particulate matter. Visually inspect KYBELLA vials for particulate matter and/or discoloration, and discard the vial if the solution is discolored and/or contains particulate matter.  </paragraph>
                        <paragraph>After use, discard any remaining solution in the vial.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_3__Injection">
                     <id root="25a2cfbb-035d-4cba-af4c-a7a2c7924fce"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.</content>
                        <content styleCode="bold">3</content>
                        <content styleCode="bold"> </content>
		     
	<content styleCode="bold">Injection Technique</content>
                     </title>
                     <text>
                        <paragraph>The safe and effective use of KYBELLA depends on the use of the correct number and locations for injections, proper needle placement, and administration techniques. </paragraph>
                        <paragraph>Healthcare professionals administering KYBELLA must understand the relevant submental anatomy and associated neuromuscular structures in the area involved and any alterations to the anatomy due to prior surgical or aesthetic procedures <content styleCode="italics">[</content>
                           <content styleCode="italics">see W</content>
                           <content styleCode="italics">a</content>
                           <content styleCode="italics">r</content>
                           <content styleCode="italics">n</content>
                           <content styleCode="italics">in</content>
                           <content styleCode="italics">g</content>
                           <content styleCode="italics">s</content>
                           <content styleCode="italics"> </content>
                           <content styleCode="italics">a</content>
                           <content styleCode="italics">n</content>
                           <content styleCode="italics">d</content>
                           <content styleCode="italics"> </content>
                           <content styleCode="italics">Preca</content>
                           <content styleCode="italics">u</content>
                           <content styleCode="italics">ti</content>
                           <content styleCode="italics">o</content>
                           <content styleCode="italics">ns (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_5_WARNINGS_AND">5</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold underline">Avoid </content>
                           <content styleCode="bold underline">injections near </content>
                           <content styleCode="bold underline">the </content>
                           <content styleCode="bold underline">area of the </content>
                           <content styleCode="bold underline">marginal mandibular </content>
                           <content styleCode="bold underline">nerve</content>
                           <content styleCode="bold underline"> </content>
                        </paragraph>
                        <paragraph>Needle placement with respect to the mandible is very important as it reduces the potential for injury to the marginal mandibular nerve, a motor branch of the facial nerve.  Injury to the nerve presents as an asymmetrical smile due to paresis of lip depressor muscles <content styleCode="italics">[</content>
                           <content styleCode="italics">see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_5_1_Marginal_mandibular">5.1</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>To avoid injury to the marginal mandibular nerve:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Do not inject above the inferior border of the mandible.<br/>
                           </item>
                           <item>Do not inject within a region defined by a 1-1.5 cm line below the inferior border (from the angle of the mandible to the mentum). <br/>
                           </item>
                           <item>Inject KYBELLA only within the target submental fat treatment area (see <linkHtml href="#Figure1">Figures 1</linkHtml> and <linkHtml href="#Figure3">3</linkHtml>). </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Figure 1.  Avoid the Marginal Mandibular Nerve Area</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure1" referencedObject="MM03000001"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold underline">Avoid </content>
                           <content styleCode="bold underline">injection into the platysma </content>
                        </paragraph>
                        <paragraph>Prior to each treatment session, palpate the submental area<content styleCode="bold"> to ensure sufficient </content>
                           <content styleCode="bold">submental fat</content>
                           <content styleCode="bold"> </content>and to identify subcutaneous fat between the dermis and platysma (pre-platysmal fat) within the target treatment area (<linkHtml href="#Figure2">Figure 2</linkHtml>).  The number of injections and the number of treatments should be tailored to the individual patient’s submental fat distribution and treatment goals. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure </content>
                           <content styleCode="bold">2</content>
                           <content styleCode="bold">. Sagittal View of Platy</content>
                           <content styleCode="bold">s</content>
                           <content styleCode="bold">ma Area</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure2" referencedObject="MM03000002"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold underline">Injecting </content>
                           <content styleCode="bold underline">into the treatment area</content>
                        </paragraph>
                        <paragraph>Use of ice/cold packs, topical and/or injectable local anesthesia (e.g., lidocaine) may enhance patient comfort.</paragraph>
                        <paragraph>Outline the planned treatment area with a surgical pen and apply a 1 cm injection grid to mark the injection sites (<linkHtml href="#Figure2">Figures 2</linkHtml> and <linkHtml href="#Figure3">3</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure </content>
                           <content styleCode="bold">3</content>
                           <content styleCode="bold">. </content>
                           <content styleCode="bold">Treatment Area and </content>
                           <content styleCode="bold">Injection Pattern</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure3" referencedObject="MM03000003"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Do not inject </content>
                           <content styleCode="bold">KYBELLA</content>
                           <content styleCode="bold"> outside the defined parameters </content>
                           <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_5_1_Marginal_mandibular">5.1</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#_5_4__Risk">5.4</linkHtml>
                           </content>
                           <content styleCode="italics">,</content>
                           <content styleCode="italics"> </content>
                           <content styleCode="italics">
                              <linkHtml href="#Section5_6">5.6</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Using a large bore needle, draw 1 mL of KYBELLA into a sterile 1 mL syringe and expel any air bubbles in the syringe barrel.  <br/>
                           </item>
                           <item>Have the patient tense the platysma. Pinch the submental fat and, using a 30 gauge (or smaller) 0.5 inch needle, inject 0.2 mL of KYBELLA into the pre-platysmal fat (see <linkHtml href="#Figure2">Figure 2</linkHtml>) next to each of the marked injection sites by advancing the needle perpendicular to the skin. <br/>
                           </item>
                           <item>Injections that are too superficial (into the dermis) may result in skin ulceration and necrosis. Do not withdraw the needle from the subcutaneous fat during injection as this could increase the risk of intradermal exposure and potential skin ulceration and necrosis.<br/>
                           </item>
                           <item>Avoid injecting into the post-platysmal fat by injecting KYBELLA into fat tissue at the depth of approximately mid-way into the subcutaneous fat layer (<linkHtml href="#Figure2">Figure 2</linkHtml>). <br/>
                           </item>
                           <item>If at any time resistance is met as the needle is inserted, indicating the possibility of contact with fascial or nonfat tissue, the needle must be withdrawn to an appropriate depth before the injection is administered.<br/>
                           </item>
                           <item>Avoid injecting into other tissues such as the muscle, salivary glands, lymph nodes; and artery or vein. <br/>
                           </item>
                           <item>Upon needle withdrawal, pressure may be applied to each injection site as necessary to minimize bleeding; an adhesive dressing may be applied. </item>
                        </list>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3_DOSAGE_FORMS">
               <id root="78294168-aab9-4ad3-b016-a8067d187b11"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3</content>
		     
	<content styleCode="bold">DOSAGE FORMS AND STRENG</content>
                  <content styleCode="bold">T</content>
                  <content styleCode="bold">HS</content>
               </title>
               <text>
                  <paragraph>Injection: 10 mg/mL.</paragraph>
                  <paragraph>KYBELLA<sup> </sup>(deoxycholic acid) injection is a clear, colorless, sterile solution supplied in 2 mL vials intended for single patient use.  Each milliliter of the solution contains 10 mg of deoxycholic acid. </paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 10 mg/mL. (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_4_CONTRAINDICATIONS">
               <id root="4913df30-6949-42f9-b760-37c5fa230577"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4</content>
                  <content styleCode="bold">
		     
	CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>KYBELLA injection is contraindicated in the presence of infection at the injection sites.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>KYBELLA is contraindicated:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>In the presence of infection at the injection sites<content styleCode="italics">. </content>(<linkHtml href="#_4_CONTRAINDICATIONS">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_5_WARNINGS_AND">
               <id root="ff882b4d-2716-46ef-b734-2461a35ac435"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5</content>
                  <content styleCode="bold">
		     
	WARNINGS AND</content>
                  <content styleCode="bold"> </content>
                  <content styleCode="bold">PR</content>
                  <content styleCode="bold">E</content>
                  <content styleCode="bold">CAUTIONS</content>
               </title>
               <effectiveTime value="20241030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Marginal mandibular nerve (MMN) injury: Follow injection technique to avoid this injury. (<linkHtml href="#_2_3__Injection">2.3</linkHtml>, <linkHtml href="#_5_1_Marginal_mandibular">5.1</linkHtml>)<br/>
                           </item>
                           <item>Dysphagia may occur with KYBELLA use.  Use in patients with pre-existing dysphagia may exacerbate the condition. (<linkHtml href="#_5_2_Dysphagia">5.2</linkHtml>)<br/>
                           </item>
                           <item>Submental hematoma/bruising occurs frequently after KYBELLA administration.  Use with caution in patients who are being treated with antiplatelet or anticoagulant therapy or have coagulation abnormalities. (<linkHtml href="#_5_3_Injection_site">5.3</linkHtml>)<br/>
                           </item>
                           <item>Avoid injecting in proximity to vulnerable anatomic structures due to the increased risk of tissue damage and vascular injury. (<linkHtml href="#_2_3__Injection">2.3</linkHtml>, <linkHtml href="#_5_4__Risk">5.4</linkHtml>)<br/>
                           </item>
                           <item>Injection site alopecia: Withhold subsequent treatments until resolution. (<linkHtml href="#_5_5_Injection_site">5.5</linkHtml>) <br/>
                           </item>
                           <item>Injection site ulceration, necrosis, and infection: Do not administer to the affected area until complete resolution. (<linkHtml href="#Section5_6">5.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Marginal_mandibular">
                     <id root="8be0f975-e6c6-4ad0-ac49-c3bee8f174e3"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5</content>
                        <content styleCode="bold">.</content>
                        <content styleCode="bold">1</content>
		     
	<content styleCode="bold">Marginal mandibular nerve injury</content>
                     </title>
                     <text>
                        <paragraph>Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness (paresis), were reported during clinical trials.  To avoid the potential for nerve injury, KYBELLA injection should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve. All marginal mandibular nerve injuries reported from the trials resolved spontaneously (range 1-298 days, median 44 days).</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_2_Dysphagia">
                     <id root="3223df82-8afd-4ebd-ac9a-2b7244f894cc"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5</content>
                        <content styleCode="bold">.</content>
                        <content styleCode="bold">2</content>
		     
	<content styleCode="bold">Dysphagia</content>
                     </title>
                     <text>
                        <paragraph>Difficulty swallowing (dysphagia) occurred in clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area.  Cases of dysphagia spontaneously resolved (range 1-81 days, median 3 days). </paragraph>
                        <paragraph>Subjects with current or prior history of dysphagia were excluded from clinical trials.  Avoid use of KYBELLA in these patients as current or prior history of dysphagia may exacerbate the condition. </paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_3_Injection_site">
                     <id root="fcaa4ca7-fd5d-43c7-bd61-a2f2bc12b5c6"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.3</content>
		     
	<content styleCode="bold">Injection site hematoma</content>
                        <content styleCode="bold">/bruising</content>
                        <content styleCode="bold"> </content>
                     </title>
                     <text>
                        <paragraph>In clinical trials, 72% of subjects treated with KYBELLA experienced injection site hematoma/bruising <content styleCode="italics">[see Adverse Reactions</content>
                           <content styleCode="italics"> </content>
                           <content styleCode="italics">(</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>. </paragraph>
                        <paragraph>KYBELLA should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur. </paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_4__Risk">
                     <id root="f6794bc2-aa58-4956-9a03-a75e7257e681"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.4</content>
                        <content styleCode="bold"> </content>
		     
	<content styleCode="bold">Risk </content>
                        <content styleCode="bold">of injecting in</content>
                        <content styleCode="bold"> proximity to vulnerable anatomic structure</content>
                        <content styleCode="bold">s</content>
                     </title>
                     <text>
                        <paragraph>To avoid potential tissue damage, KYBELLA should not be injected into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.</paragraph>
                        <paragraph>Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury. </paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_5_Injection_site">
                     <id root="476db33b-61ef-4428-9f32-4564c7ec93b5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.5</content>
                        <content styleCode="bold">
		     
	Injection site alopecia</content>
                     </title>
                     <text>
                        <paragraph>Cases of injection site alopecia have been reported with the administration of KYBELLA. The onset and duration of this adverse reaction may vary among individuals and may persist. Consider withholding subsequent treatments until resolution of the adverse reaction.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section5_6">
                     <id root="5a8f461e-e722-48eb-8723-da5f3cb8d434"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.6</content>
                        <content styleCode="bold">
		     
	Injection site ulceration</content>
                        <content styleCode="bold">,</content>
                        <content styleCode="bold"> necrosis</content>
                        <content styleCode="bold">, and infection</content>
                     </title>
                     <text>
                        <paragraph>Injections that are too superficial (into the dermis) may result in skin ulceration and necrosis <content styleCode="italics">[see Injection Technique (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_3__Injection">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Cases of injection site ulceration, necrosis, and infection have been reported with the administration of KYBELLA. Some cases of injection site infection have included cellulitis and abscess requiring intravenous antibiotic treatment and incision and drainage. Do not administer KYBELLA into the affected area until complete resolution of the adverse reaction.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="4eca39e5-c319-447f-80bc-f58155f103a9"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6</content>
                  <content styleCode="bold">
		     
	ADVERSE REACTIONS</content>
                  <content styleCode="bold"> </content>
               </title>
               <effectiveTime value="20241030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (&gt;20% of subjects) include injection site edema/swelling, hematoma, pain, numbness, erythema and induration. (<linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-678-1605  or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1_Clinical_Trials">
                     <id root="d516e58c-bee8-45f4-b599-71d1489a9dba"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90374-0" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6</content>
                        <content styleCode="bold">.</content>
                        <content styleCode="bold">1</content>
                        <content styleCode="bold">
		     
	Clinical Trials Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In two double-blind, placebo-controlled clinical trials 513 subjects were treated with KYBELLA injection and 506 subjects were treated with placebo.  The population was 19-65 years old, 85% were women, 87% Caucasian, 8% African American.  At baseline the population had a mean BMI of 29 kg/m<sup>2</sup>, moderate to severe submental convexity (graded as 2 or 3 on a 0 to 4 scale) and without excessive skin laxity.  Subjects received up to 6 treatments at least 1 month apart and were followed for up to 6 months after the last received treatment.</paragraph>
                        <paragraph>The most commonly reported adverse reactions are listed below (<linkHtml href="#Table1">Table 1</linkHtml>).</paragraph>
                        <table ID="Table1">
                           <caption>Table 1. Adverse Reactions in the Pooled Trials 1 and 2<sup>a</sup>
                           </caption>
                           <col width="147"/>
                           <col width="109"/>
                           <col width="126"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <br/>Adverse reactions</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">KYBELLA<br/>(N=513)<br/>n (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Placebo<br/>(N=506)<br/>n (%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Injection site reactions</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">492 (96%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">411 (81%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">         edema/swelling</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">448 (87%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">218 (43%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">         hematoma/bruising</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">368 (72%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">353 (70%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">         pain</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">356 (70%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">160 (32%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">         numbness</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">341 (66%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">29 (6%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">         erythema</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">136 (27%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">91 (18%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">         induration</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">120 (23%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13 (3%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">         paresthesia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">70 (14%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20 (4%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">         nodule</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">68 (13%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14 (3%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">         pruritus</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">64 (12%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30 (6%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">         skin tightness</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">24 (5%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6 (1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">         site warmth</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22 (4%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8 (2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">         nerve injury<sup> b</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20 (4 %)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 (&lt;1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Headache</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">41 (8%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20 (4%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Oropharyngeal pain</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15 (3%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7 (1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Hypertension</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13 (3%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7 (1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Nausea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12 (2%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3 (1%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Dysphagia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10 (2%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 (&lt;1%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a </sup>Adverse reactions that occurred in ≥ 2% KYBELLA treated subjects and at greater incidence than placebo<br/>
                           <sup>b</sup> Marginal mandibular nerve paresis</paragraph>
                        <paragraph>Other adverse reactions associated with the use of KYBELLA include: injection site hemorrhage, injection site discoloration, pre-syncope/syncope, lymphadenopathy, injection site urticaria, and neck pain.</paragraph>
                        <paragraph>Adverse reactions that lasted more than 30 days and occurred in more than 10% of subjects were injection site numbness (42%), injection site edema/swelling (20%), injection site pain (16%), and injection site induration (13%). </paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8ef82f40-87bd-478d-ab9d-138df964db47"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90375-7" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.2</content>
		     
	<content styleCode="bold">Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of KYBELLA.</paragraph>
                        <paragraph>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Administration site conditions</content>: injection site ulceration, necrosis, infection, alopecia, scarring, and mass. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System Disorders:</content>
                           <content styleCode="bold"> </content>Hypersensitivity reactions including rash, urticaria, and itching.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders:</content> Oral hypoaesthesia and oral paraesthesia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Procedural Complications: </content>Vascular injury due to inadvertent intravascular injection.<sup> </sup>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="954131c0-8bca-4c3e-b505-f568af4192ca"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8</content>
                  <content styleCode="bold">
		     
	USE IN SPECIFIC</content>
                  <content styleCode="bold"> </content>
                  <content styleCode="bold">POP</content>
                  <content styleCode="bold">U</content>
                  <content styleCode="bold">L</content>
                  <content styleCode="bold">A</content>
                  <content styleCode="bold">TIO</content>
                  <content styleCode="bold">N</content>
                  <content styleCode="bold">S</content>
               </title>
               <effectiveTime value="20241030"/>
               <component>
                  <section>
                     <id root="6c818dca-5f36-42f2-8481-e61f711aabeb"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8</content>
                        <content styleCode="bold">.</content>
                        <content styleCode="bold">1</content>
                        <content styleCode="bold">
		     
	Preg</content>
                        <content styleCode="bold">n</content>
                        <content styleCode="bold">a</content>
                        <content styleCode="bold">n</content>
                        <content styleCode="bold">c</content>
                        <content styleCode="bold">y</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no adequate and well-controlled studies of KYBELLA injection in pregnant women to inform the drug-associated risk.    In animal reproduction studies, no fetal harm was observed with the subcutaneous administration of deoxycholic acid to rats during organogenesis at doses up to 5 times the maximum recommended human dose (MRHD) of 100 mg <content styleCode="italics">[see Data]</content>
                           <content styleCode="italics">.</content> </paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown.  However, the background risk of major birth defects in the U.S. general population is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Animal Data</content>
                        </paragraph>
                        <paragraph>Embryofetal development studies have been performed in rats and rabbits using subcutaneous doses of deoxycholic acid administered during the period of organogenesis.  For the basis of comparing animal to human doses, the MRHD is 1.7 mg/kg (100 mg/60 kg).  No evidence of fetal harm was observed in rats at up to the highest dose tested (50 mg/kg) which is 5-fold higher than the MRHD of KYBELLA based on a mg/m<sup>2</sup> comparison.  However, missing intermediate lung lobe was noted in rabbits at all dose levels tested including the lowest dose (10 mg/kg) which is 2-fold higher than the MRHD of KYBELLA based on a mg/m<sup>2</sup> comparison.  These effects may be related to maternal toxicity, which was also seen at all dose levels tested.   </paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="6fac5e57-dca7-475e-b81a-6160d6c760d0"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8</content>
                        <content styleCode="bold">.</content>
                        <content styleCode="bold">2</content>
		     
	<content styleCode="bold">Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Risk Summary</content>
                        </paragraph>
                        <paragraph>There is no information available on the presence of synthetic deoxycholic acid in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production.  The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for KYBELLA and any potential adverse effects on the breastfed child from KYBELLA or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="34efc9ab-462a-4292-b34c-869ff633b34f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8</content>
                        <content styleCode="bold">.</content>
                        <content styleCode="bold">4</content>
                        <content styleCode="bold">
		     
	Ped</content>
                        <content styleCode="bold">i</content>
                        <content styleCode="bold">atr</content>
                        <content styleCode="bold">i</content>
                        <content styleCode="bold">c</content>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">Use</content>
                     </title>
                     <text>
                        <paragraph>Safety and effectiveness in patients below the age of 18 years have not been established and KYBELLA is not intended for use in children or adolescents.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8a84013d-fc30-4759-b8bf-8d341c977558"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5</content>
                        <content styleCode="bold">
		     
	Geriatric</content>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">Use</content>
                     </title>
                     <text>
                        <paragraph>The clinical trials of KYBELLA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="7554eebe-5dd2-4545-a14f-5256db7021f7"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11</content>
                  <content styleCode="bold">
		     
	DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>KYBELLA (deoxycholic acid) injection, 10 mg/mL is a clear colorless, sterile solution for subcutaneous use.  It contains a cytolytic agent, deoxycholic acid, as the active ingredient.  The chemical name of deoxycholic acid is 3α,12α-dihydroxy-5β-cholan-24-oic acid, and its molecular formula is C<sub>24</sub>H<sub>40</sub>O<sub>4</sub>, and its molecular weight is 392.57 g/mol.  The chemical structure of deoxycholic acid is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000004"/>
                  </paragraph>
                  <paragraph>Each 2 mL vial of KYBELLA injection contains 20 mg synthetic deoxycholic acid as the active ingredient and the following inactive ingredients: benzyl alcohol (18 mg), dibasic sodium phosphate (2.84 mg), sodium chloride (8.76 mg), sodium hydroxide (2.86 mg) in water for injection, USP.  Hydrochloric acid and additional sodium hydroxide are added as necessary to adjust the formulation to pH 8.3.  Each vial is for single patient use. </paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <component>
                  <observationMedia ID="MM03000004">
                     <text>The chemical structure of deoxycholic acid.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="kybella-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="66c8c508-94b6-4a67-9a29-231c8a2f6cf5"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12</content>
                  <content styleCode="bold">
		     
	CLINICAL</content>
                  <content styleCode="bold"> </content>
                  <content styleCode="bold">PHARMACO</content>
                  <content styleCode="bold">L</content>
                  <content styleCode="bold">OGY</content>
               </title>
               <effectiveTime value="20241030"/>
               <component>
                  <section>
                     <id root="77faea42-1968-48b3-bf6b-7c10115d1fea"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1</content>
                        <content styleCode="bold">
		     
	Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>KYBELLA<sup> </sup>injection is a cytolytic drug, which when injected into tissue physically destroys the cell membrane causing lysis. </paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="65b38cb2-829c-4f88-83fd-4091dcca2528"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">1</content>
                        <content styleCode="bold">2</content>
                        <content styleCode="bold">.2</content>
                        <content styleCode="bold">
		     
	Phar</content>
                        <content styleCode="bold">m</content>
                        <content styleCode="bold">a</content>
                        <content styleCode="bold">c</content>
                        <content styleCode="bold">o</content>
                        <content styleCode="bold">d</content>
                        <content styleCode="bold">y</content>
                        <content styleCode="bold">n</content>
                        <content styleCode="bold">a</content>
                        <content styleCode="bold">mics</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At therapeutic doses, KYBELLA does not prolong the QTc interval.</paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f0184ac9-ccc3-4c1a-a3ba-005cc85f7133"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">1</content>
                        <content styleCode="bold">2</content>
                        <content styleCode="bold">.3</content>
                        <content styleCode="bold">
		     
	Phar</content>
                        <content styleCode="bold">m</content>
                        <content styleCode="bold">a</content>
                        <content styleCode="bold">c</content>
                        <content styleCode="bold">o</content>
                        <content styleCode="bold">k</content>
                        <content styleCode="bold">in</content>
                        <content styleCode="bold">et</content>
                        <content styleCode="bold">i</content>
                        <content styleCode="bold">cs</content>
                     </title>
                     <text>
                        <paragraph>Endogenous deoxycholic acid plasma levels are highly variable within and between individuals; most of this natural bile component is sequestered in the enterohepatic circulation loop.  </paragraph>
                        <paragraph>
                           <content styleCode="italics">Absorption and Distribution</content>
                        </paragraph>
                        <paragraph>Deoxycholic acid from KYBELLA is rapidly absorbed following subcutaneous injection.  After dosing with the maximum recommended single treatment dose with KYBELLA (100 mg), maximum plasma concentrations (mean C<sub>max</sub>) were observed with a median T<sub>max</sub> of 18 minutes after injection.  The mean (±SD) C<sub>max</sub> value was 1024 ± 304 ng/mL and was 3.2-fold higher than average C<sub>max</sub> values observed during a 24-hour baseline endogenous period in the absence of KYBELLA.  After maximum recommended single treatment dose (100 mg), mean (±SD) deoxycholic acid exposure (AUC<sub>0-24</sub>) was 7896 ± 2269 ng.hr/mL and was 1.6-fold higher over endogenous exposure.  Post-treatment deoxycholic acid plasma levels returned to the endogenous range within 24 hours.  No accumulation is expected with the proposed treatment frequency. </paragraph>
                        <paragraph>Deoxycholic acid is extensively bound to proteins in plasma (98%).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and Excretion</content>
                        </paragraph>
                        <paragraph>Endogenous deoxycholic acid is a product of cholesterol metabolism and is excreted intact in feces.  Deoxycholic acid is not metabolized to any significant extent under normal conditions. Deoxycholic acid from KYBELLA joins the endogenous bile acid pool in the enterohepatic circulation and is excreted along with the endogenous deoxycholic acid.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Assessment of Drug Interactions</content>
                        </paragraph>
                        <paragraph>Results from in vitro studies indicate that deoxycholic acid does not inhibit or induce human cytochrome P450 (CYP) enzymes at clinically relevant concentrations.  Deoxycholic acid does not inhibit the following transporters: P-gp, BCRP, MRP4, MRP2, OATP1B1, OATP2B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, NTCP, and ASBT. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>KYBELLA has not been studied in subjects with hepatic impairment.  Considering the intermittent dose frequency, the small dose administered that represents approximately 3% of the total bile acid pool, and the highly variable endogenous deoxycholic acid levels, the pharmacokinetics of deoxycholic acid following KYBELLA injection is unlikely to be influenced by hepatic impairment.   </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pharmacokinetic E</content>
                           <content styleCode="underline">ffects of Gender </content>
                        </paragraph>
                        <paragraph>Deoxycholic acid pharmacokinetics were not influenced by gender. </paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="332a809f-710f-4d53-8383-3f9eeb4e57c4"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">1</content>
                  <content styleCode="bold">3</content>
                  <content styleCode="bold">
		     
	NONCLINICAL TO</content>
                  <content styleCode="bold">X</content>
                  <content styleCode="bold">ICOLOGY</content>
               </title>
               <effectiveTime value="20241030"/>
               <component>
                  <section>
                     <id root="71488739-c491-4e79-a537-558dd01a9ff2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1</content>
                        <content styleCode="bold">
		     
	Carcinogenes</content>
                        <content styleCode="bold">i</content>
                        <content styleCode="bold">s,</content>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">Mutagenes</content>
                        <content styleCode="bold">i</content>
                        <content styleCode="bold">s, Impairment of Fe</content>
                        <content styleCode="bold">r</content>
                        <content styleCode="bold">tility</content>
                     </title>
                     <text>
                        <paragraph>Long-term studies in animals have not been performed to evaluate the carcinogenic potential of KYBELLA injection. </paragraph>
                        <paragraph>KYBELLA<content styleCode="bold"> </content>was negative in a battery of in vitro (Ames test and chromosomal aberration assay in human lymphocytes) and in vivo (rat erythrocyte micronucleus assay) genetic toxicology assays.</paragraph>
                        <paragraph>No effects on fertility were observed in male and female rats administered deoxycholic acid at subcutaneous doses up to 50 mg/kg (5 times the MRHD based on a mg/m<sup>2</sup> comparison) once weekly prior to and during the mating period and through gestation day 7 in female rats.<content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="a8c1e4f7-68b0-45bb-b2e1-33d62ba1d203"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14</content>
                  <content styleCode="bold">
		     
	CLINICAL</content>
                  <content styleCode="bold"> </content>
                  <content styleCode="bold">STUDIES</content>
               </title>
               <text>
                  <paragraph>Two randomized, multi-center, double-blind, placebo-controlled trials of identical design were conducted to evaluate KYBELLA injection for use in improvement in the appearance of convexity or fullness associated with submental fat.  The trials enrolled healthy adults (ages 19 to 65, BMI ≤ 40 kg/m<sup>2</sup>) with moderate or severe convexity or fullness associated with submental fat (i.e., grade 2 or 3 on 5-point grading scales, where 0 = none and 4 = extreme), as judged by both clinician and subject ratings.  Subjects received up to 6 treatments with KYBELLA (N=514, combined trials) or placebo (N=508, combined trials) at no less than 1 month intervals.  Use of ice/cold packs, topical and/or injectable local anesthesia was allowed during the clinical trials.  Injection volume was 0.2 mL per injection site, spaced 1 cm apart into the submental fat tissue, which is also expressed in dose per area as 2 mg/cm<sup>2</sup>.  For each treatment session a maximum of 100 mg (10 mL) was permitted over the entire treatment area. Subjects were administered an average of 6.4 mL at the first treatment session, and subjects who received all six treatments were administered an average of 4.4 mL at the sixth treatment session.  Fifty-nine percent of subjects received all six treatments.</paragraph>
                  <paragraph>In these trials, the mean age was 49 years and the mean BMI was 29 kg/m<sup>2</sup>.  Most of the subjects were women (85%) and Caucasian (87%).  At baseline, 51% of the subjects had a clinician-rated submental fat severity rating of moderate and 49% had a severe submental fat rating.</paragraph>
                  <paragraph>The co-primary efficacy assessments were based on at least 2-grade and at least 1-grade improvements in submental convexity or fullness on the composite of clinician-reported and patient-reported ratings of submental fat 12 weeks after final treatment.  Additionally, changes in submental fat volume were evaluated in a subset of subjects (N=449, combined trials) using magnetic resonance imaging (MRI).  Visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were also evaluated using a 6-question survey, with each question rated from 0 (not at all) to 10 (extremely/very much). </paragraph>
                  <paragraph>Reductions in submental fat volume were observed more frequently in the KYBELLA group compared to the placebo group as measured by the composite clinician and patient ratings (<linkHtml href="#Table2">Table 2</linkHtml>).  The composite response rates by visit are presented in <linkHtml href="#Figure4">Figure 4</linkHtml>. </paragraph>
                  <table ID="Table2">
                     <caption>Table 2.  ≥ 2-Grade and ≥ 1-Grade Composite Clinician and Patient Response 12 Weeks After Final Treatment</caption>
                     <col width="222"/>
                     <col width="90"/>
                     <col width="90"/>
                     <col width="90"/>
                     <col width="90"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " valign="bottom"/>
                           <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                              <content styleCode="bold">Trial 1</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                              <content styleCode="bold">Trial 2</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " valign="bottom">
                              <content styleCode="bold">Endpoint</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">KYBELLA</content> <br/>(N=256)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">Placebo</content>
                              <br/>(N=250)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">KYBELLA</content>
                              <br/>(N=258)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">Placebo</content>
                              <br/>(N=258)</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">2-Grade Composite Response <sup>a</sup>
                              <sup> </sup>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">13.4%</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">&lt;0.1%</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">18.6%</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">3.0%</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">1-Grade Composite Response<sup> b</sup>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">70.0%</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">18.6%</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">66.5%</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">22.2%</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <sup>a</sup>
                     <sup> </sup>
                     <sup>At least 2 grade reduction on both the clinician-reported and patient-reported</sup>
                     <sup> </sup>
                     <sup>ratings of</sup>
                     <sup> </sup>
                     <sup>submental fat</sup>
                     <br/>
                     <sup>b</sup>
                     <sup> At least 1 grade reduction on both the clinician-reported and patient-reported</sup>
                     <sup> </sup>
                     <sup>ratings of</sup>
                     <sup> </sup>
                     <sup>submental fat</sup>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure </content>
                     <content styleCode="bold">4</content>
                     <content styleCode="bold">.</content>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">≥</content>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">2</content>
                     <content styleCode="bold">-Grade and </content>
                     <content styleCode="bold">≥</content>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">1</content>
                     <content styleCode="bold">-Grade Composite Clinician and Patient Response</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia ID="Figure4" referencedObject="MM03000005"/>
                  </paragraph>
                  <paragraph>Note: Subjects were followed up 4, 12 and 24 weeks after the last treatment.  Forty-one percent of subjects received fewer than 6 treatments and entered the post-treatment period earlier than Week 24.</paragraph>
                  <paragraph>A greater proportion of KYBELLA-treated subjects had at least a 10% reduction in submental fat volume as compared to placebo-treated subjects when evaluated by MRI (43% vs 5%, respectively). </paragraph>
                  <paragraph>The overall patient-reported satisfaction and self-perceived visual attributes showed greater improvement in the KYBELLA group than in the placebo group.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <component>
                  <observationMedia ID="MM03000005">
                     <text>Figure 5.  ≥ 2-Grade and ≥ 1-Grade Composite Clinician and Patient Response</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="kybella-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="f29610f3-cd7a-4ec3-80bf-7b1967d31fd7"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">1</content>
                  <content styleCode="bold">6</content>
                  <content styleCode="bold">
		     
	HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>KYBELLA (deoxycholic acid) injection, 10 mg/mL is a clear, colorless, sterile solution supplied in 2 mL, single patient use vials in the following dispensing pack:</paragraph>
                  <paragraph>4 vials, NDC 61168-101-04</paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F)  [See USP Controlled Room Temperature].</paragraph>
                  <paragraph>KYBELLA<sup> </sup>has a unique hologram on the vial label.  If you do not see a hologram, do not use the product and call 1-800-678-1605. </paragraph>
                  <paragraph>Each vial is for a single patient use.  Do not dilute or mix KYBELLA with other compounds.  Discard unused portion.</paragraph>
               </text>
               <effectiveTime value="20241030"/>
            </section>
         </component>
         <component>
            <section ID="_17_PATIENT_COUNSELING">
               <id root="592e7f68-dd9c-4089-9dd4-0eaf303d79a8"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">1</content>
                  <content styleCode="bold">7</content>
                  <content styleCode="bold">
		     
	PATIENT COUNSELING INFORMA</content>
                  <content styleCode="bold">T</content>
                  <content styleCode="bold">ION</content>
               </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#PatientInformation">Patient Information</linkHtml>).</paragraph>
                  <paragraph>Advise patients to contact their healthcare providers if patients begin to develop signs of marginal mandibular nerve paresis (e.g., asymmetric smile, facial muscle weakness), difficulty swallowing, or worsening of existing symptoms.  </paragraph>
                  <paragraph>Advise patients to contact their healthcare providers for development of erythema, pain, open sore(s) or drainage from the treatment area.</paragraph>
                  <paragraph>Distributed by: AbbVie Inc.</paragraph>
                  <paragraph>Manufactured for:<br/>AbbVie Inc.<br/>North Chicago, IL 60064<br/>
                     <br/>
                     <br/>© 2024 AbbVie. All rights reserved.<br/>KYBELLA<sup>®</sup> and its design are registered trademarks of Allergan Sales, LLC, an AbbVie company.</paragraph>
                  <paragraph>
                     <br/>Patented. See www.abbvie.com/patents</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000006"/>
                  </paragraph>
                  <paragraph>v4.0USPI0101</paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <component>
                  <observationMedia ID="MM03000006">
                     <text>Shape

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="kybella-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="df4e9433-94ec-454e-bc25-69f990c3d380"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42230-3" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title/>
               <text>
                  <table ID="PatientInformation">
                     <col width="344"/>
                     <col width="164"/>
                     <col width="247"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3" align="center">
                              <content styleCode="bold">Patient Information</content>
                              <br/>
                              <content styleCode="bold">KYBELLA</content>
                              <content styleCode="bold">
                                 <sup>®</sup>
                              </content>
                              <content styleCode="bold"> (kye be lah)</content>
                              <br/>
                              <content styleCode="bold">(deoxycholic acid</content>
                              <content styleCode="bold">)</content>
                              <br/>
                              <content styleCode="bold">injection</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">What is KYBELLA</content>
                              <content styleCode="bold">?</content>
                              <br/>KYBELLA is a prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called “double chin.”<br/>It is not known if KYBELLA is safe and effective for the treatment of fat outside of the submental area.<br/>It is not known if KYBELLA is safe and effective in children under 18 years of age.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Do</content>
                              <content styleCode="bold"> not receive KYBELLA if</content> you have an infection in the treatment area.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Before receiving </content>
                              <content styleCode="bold">KYBELLA</content>
                              <content styleCode="bold">, tell your healthcare provider about all of your medical conditions, including if you:  </content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have had or plan to have surgery on your face, neck, or chin<br/>
                                 </item>
                                 <item>have had cosmetic treatments on your face, neck, or chin  <br/>
                                 </item>
                                 <item>have had or have medical conditions in or near the neck area<br/>
                                 </item>
                                 <item>have had or have trouble swallowing<br/>
                                 </item>
                                 <item>have bleeding problems<br/>
                                 </item>
                                 <item>are pregnant or plan to become pregnant. It is not known if KYBELLA will harm your unborn baby. <br/>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if KYBELLA passes into your breast milk. </item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take a medicine that prevents the clotting of your blood (antiplatelet or anticoagulant medicine). </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">How will I receive </content>
                              <content styleCode="bold">KYBELLA</content>
                              <content styleCode="bold">?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>KYBELLA is injected into the fat under your chin (up to 50 injections under your skin) by your healthcare provider. <br/>
                                 </item>
                                 <item>KYBELLA injections may be given at least 1 month apart. You and your healthcare provider will decide how many treatments you need.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">What are the possible side effects of </content>
                              <content styleCode="bold">KYBELLA</content>
                              <content styleCode="bold">?</content>
                              <br/>
                              <content styleCode="bold">KYBELLA </content>
                              <content styleCode="bold">can cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Nerve injury in the jaw that can cause an uneven smile or facial muscle weakness</content>
                                    <content styleCode="bold">.</content>
                                    <content styleCode="bold"> </content>
                                    <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Trouble swallowing</content>
                                    <content styleCode="bold">.</content>
                                    <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Injection site problems including:</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>a collection of blood under the skin (hematoma) or bruising <br/>
                                       </item>
                                       <item>damage to an artery or vein if KYBELLA is inadvertently injected into it<br/>
                                       </item>
                                       <item>hair loss<br/>
                                       </item>
                                       <item>open sores (ulcers)<br/>
                                       </item>
                                       <item>damage and tissue cell-death (necrosis) around the injection site<br/>
                                       </item>
                                       <item>infection</item>
                                    </list>
                                 </item>
                              </list>
                              <content styleCode="bold">Call your healthcare provider if you</content>:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>begin to develop weakness in the muscles of your face, or your smile becomes uneven<br/>
                                 </item>
                                 <item>you have difficulty swallowing, or if any of the symptoms that you already have get worse<br/>
                                 </item>
                                 <item>develop redness, pain, open sores, or drainage at or from the treatment area   </item>
                              </list>
                              <content styleCode="bold">The most common side effects of </content>
                              <content styleCode="bold">KYBELLA </content>
                              <content styleCode="bold">include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <content styleCode="bold">● </content>swelling</td>
                           <td styleCode="Rrule " colspan="2">
                              <content styleCode="bold">● </content>redness</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <content styleCode="bold">●</content> pain</td>
                           <td styleCode="Rrule " colspan="2">
                              <content styleCode="bold">● </content>areas of hardness in the treatment area</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <content styleCode="bold">●</content> numbness</td>
                           <td styleCode="Rrule " colspan="2"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="3">These are not all of the possible side effects of KYBELLA.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">General information about the safe and effective use of </content>
                              <content styleCode="bold">KYBELLA.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for more information about KYBELLA that is written for health professionals.  </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">What are the ingredients in </content>
                              <content styleCode="bold">KYBELLA</content>
                              <content styleCode="bold">? </content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> deoxycholic acid
		     
	<br/>
                              <content styleCode="bold">Inactive ingredients:</content> benzyl alcohol, dibasic sodium phosphate, hydrochloric acid, sodium chloride, sodium hydroxide and water for injection, USP. </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">Distributed by: AbbVie Inc.<br/>Manufactured for:<br/>AbbVie Inc.<br/>North Chicago, IL 60064<br/>© 2024 AbbVie. All rights reserved. <br/>KYBELLA<sup>®</sup> and its design are registered trademarks of Allergan Sales, LLC, an AbbVie <br/>company. <br/>Patented. See www.abbvie.com/patents<br/>For more information about KYBELLA go to www.mykybella.com.<br/>
                           </td>
                           <td styleCode="Rrule ">
                              <renderMultiMedia referencedObject="MM03000006"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.                                   Revised: 10/2024</paragraph>
                  <paragraph>v4.0PPI0101</paragraph>
               </text>
               <effectiveTime value="20241030"/>
            </section>
         </component>
         <component>
            <section>
               <id root="cb8ecef2-2696-4882-aa32-72c31e699256"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel</content>
                  </paragraph>
                  <paragraph>NDC: 61168-101-04<br/>
                     <content styleCode="bold">kybella</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <br/>(deoxycholic acid) injection 10 mg/mL<br/>
                     <content styleCode="bold">20 mg/2 mL</content>
                     <br/>(10 mg/mL)<br/>for subcutaneous use only<br/>
                  </paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>Single use vials. Discard unused portion.</paragraph>
                  <paragraph>Four ready-to-use vials. Do not dilute.</paragraph>
                  <paragraph>Rx ONLY</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000007"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000008"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241030"/>
               <component>
                  <observationMedia ID="MM03000007">
                     <text>Allergan logo</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="kybella-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000008">
                     <text>Principal Display Panel
NDC: 61168-101-04
kybella®
(deoxycholic acid) injection 10 mg/mL
20 mg/2 mL
(10 mg/mL)
for subcutaneous use only



Single use vials. Discard unused portion.
Four ready-to-use vials. Do not dilute.
Rx ONLY
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="kybella-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>